Screener
Neurocrine Biosciences NBIX Free cash flow margin
Free cash flow margin at other companies
Other financials
Where this comes from
Calculated from Neurocrine Biosciences’s reported figures.
Based on trailing twelve months.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
FAQ
- What is Neurocrine Biosciences's free cash flow margin?
- Neurocrine Biosciences (NBIX) reported free cash flow margin of 26.8% in Q1 2026.
- How has Neurocrine Biosciences's free cash flow margin changed year-over-year?
- Neurocrine Biosciences's free cash flow margin increased by 31.3% year-over-year, from 20.4% to 26.8%.
- What is the long-term trend for Neurocrine Biosciences's free cash flow margin?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's free cash flow margin has grown at a 2.8% compound annual growth rate (CAGR), from 22.8% to 26.2%.
- What does free cash flow margin mean?
- Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.
Ask your AI about Neurocrine Biosciences's free cash flow margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude